GoLiver Therapeutics is at the forefront of regenerative medicine, focusing on innovative solutions for liver repair without the need for grafts. The company is developing advanced therapies utilizing pluripotent stem cells, which can differentiate into various cell types, including hepatocytes. This approach aims to address the critical shortage of donor organs for liver transplantation by providing an unlimited source of liver cells produced in vitro. Their injectable cell therapy product is designed to treat a range of liver diseases, including acute liver failure, cirrhosis, and genetic disorders, offering a promising alternative to traditional transplant methods.

The technology behind GoLiver Therapeutics leverages the unique regenerative capabilities of the liver, aiming to harness the potential of human pluripotent stem cells to create a sustainable and effective treatment option. By focusing on the industrialization of cell therapy production, the company seeks to scale up the manufacturing process to produce billions of cells, thereby enhancing the availability of therapeutic solutions. This innovative approach not only holds the promise of improving patient outcomes but also positions GoLiver Therapeutics as a potential leader in the future of liver regenerative medicine.

France

GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation.

GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.

GoLiver Therapeutics

Company Details